Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

|Videos|January 3, 2023

Expert discusses what is on the horizon for stone disease in coming years

Author(s)Urology Times staff

“As people think about how we can do stone surgery more effectively, less morbidly for our patients, and less invasively, I think we're going to see robots enter our picture,” says Thomas Chi, MD.

In this interview, Thomas Chi, MD, predicts what might be on the horizon for stone disease in the coming years, and he discusses some of his own research interests within the field. Chi is a professor and associate chair at the University of California, San Francisco.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

New Frontiers in Suction and Stone Removal

ByKaren L. Stern, MD,Naeem Bhojani, MD, FRCSC

December 5th 2025

How Suction Is Redefining Ureteroscopy and PCNL Practices

ByKaren L. Stern, MD,Naeem Bhojani, MD, FRCSC

December 5th 2025

CVAC 2.0 and Beyond: Aspiration-Driven Ureteroscopy

ByKaren L. Stern, MD,Naeem Bhojani, MD, FRCSC

December 5th 2025

Direct-in-Scope Suction: Advantages and Limitations

ByKaren L. Stern, MD,Naeem Bhojani, MD, FRCSC

December 5th 2025

The Rise of Suction and an Overview of FANS

ByKaren L. Stern, MD,Naeem Bhojani, MD, FRCSC

December 5th 2025

Latest CME

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Wisconsin

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Wisconsin

Scott T. Tagawa, MD, MS, FACP, FASCO; Kate Baxstrom, MD

DSUI Urology on the Beach

In-Person Event

DSUI Urology on the Beach

January 16-18, 2026

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Jason M. Hafron, MD

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Aaron D. Berger, MD

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Stacy Loeb, MD, MSc, PhD (Hon)

Trending on Urology Times

Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men

FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC

FDA approves first-line Zenflow system for the treatment of BPH

FDA approves zoliflodacin for uncomplicated urogenital gonorrhea

EMA recommends conditional approval of Anktiva in BCG-unresponsive NMIBC

© 2025 MJH Life Sciences^®

All rights reserved.